Drug Type Biosimilar, Enzyme |
Synonyms Agalsidase Beta Biosimilar (Generium ZAO), 阿加糖酶β生物类似药(Generium ZAO), GNR-062 + [1] |
Target |
Action inhibitors |
Mechanism GL3 inhibitors(Globotriaosylceramide inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fabry Disease | Phase 1 | Russia | 02 Mar 2023 |






